# FDA Regulations Reference Guide

Quick lookup guide for FDA regulations, pathways, timelines, and requirements.

**Version:** 1.0.0
**Last Updated:** 2024-11-16
**Source:** Based on publicly available FDA regulations and guidance as of November 2024

---

## Table of Contents

1. [FDA Regulatory Pathways Quick Reference](#fda-regulatory-pathways-quick-reference)
2. [Critical FDA Regulations (21 CFR)](#critical-fda-regulations-21-cfr)
3. [FDA Review Timelines](#fda-review-timelines)
4. [Device Risk Classification](#device-risk-classification)
5. [Common FDA Guidance Documents](#common-fda-guidance-documents)
6. [FDA Contact Information](#fda-contact-information)
7. [FDA Acronyms & Definitions](#fda-acronyms--definitions)

---

## FDA Regulatory Pathways Quick Reference

### Medical Device Pathways

| Pathway | Device Class | Timeline (FDA Review) | Success Rate | Key Requirements |
|---------|--------------|----------------------|--------------|------------------|
| **Exempt** | Class I (most), Some Class II | Immediate | N/A | Registration & Listing only |
| **510(k)** | Class II (most), Some Class I | 90 days (MDUFA goal) | ~85% | Substantial Equivalence to predicate |
| **De Novo** | Novel Class I/II | 150 days (MDUFA goal) | ~75% | No predicate available, demonstrate safety/effectiveness |
| **PMA** | Class III | 180-360 days | ~70% | Clinical data demonstrating safety and effectiveness |
| **HDE** | Rare Disease (<8,000 patients/year) | 180 days | ~80% | Probable benefit, humanitarian use |
| **EUA** | Emergency Use | Variable | Case-by-case | Public Health Emergency declared |

**Additional Timeline Context:**
- **510(k) Total Time**: Typically 3-6 months including submission preparation
- **PMA Total Time**: Typically 12-24 months including FDA review and potential panel review
- **De Novo Total Time**: Typically 5-8 months total

### Drug/Biologic Pathways

| Application Type | Product Type | Review Timeline (FDA) | Standard | Key Features |
|-----------------|--------------|----------------------|----------|--------------|
| **IND** | Investigational Drug/Biologic | 30 days (goes into effect if no hold) | Phase I/II/III trials | Enables clinical investigation |
| **NDA** | New Drug | 10 months (standard), 6 months (priority) | Novel chemical entity | Full safety and efficacy data |
| **ANDA** | Generic Drug | 10 months (standard) | Generic of approved drug | Bioequivalence to reference product |
| **BLA** | Biologic | 10 months (standard), 6 months (priority) | Biological product | Manufacturing and characterization |
| **505(b)(2)** | Modified Drug | 10 months (standard) | Relies on prior data | Changes to approved drug |

**PDUFA VII Goals (2023-2027):**
- Standard Review: 10 months for original applications
- Priority Review: 6 months for original applications
- Resubmissions: 2-6 months depending on type

---

## Critical FDA Regulations (21 CFR)

### Medical Device Regulations

#### Part 807 - Establishment Registration and Device Listing
**Key Sections:**
- **§807.20-40**: Registration requirements - All device establishments must register annually
- **§807.81-97**: Premarket notification (510(k)) procedures
- **§807.100**: FDA action on 510(k) - Substantially Equivalent (SE), Not Substantially Equivalent (NSE), or additional information requested

**Common Requirements:**
- Annual registration renewal (October-December)
- Device listing for all marketed devices
- 510(k) submission at least 90 days before marketing (unless exempt)

#### Part 812 - Investigational Device Exemptions (IDE)
**Key Sections:**
- **§812.20**: IDE application requirements
- **§812.35**: Significant risk vs. non-significant risk determination
- **§812.140**: Records and reports - serious adverse events, unanticipated device effects

**Significant Risk Devices:**
- Require FDA approval before study starts
- Full IDE application with protocol, investigator qualifications, informed consent
- IRB approval required

**Non-Significant Risk Devices:**
- Abbreviated IDE process
- IRB approval sufficient to proceed
- FDA notification via annual progress reports

#### Part 814 - Premarket Approval (PMA)
**Key Sections:**
- **§814.20**: PMA application contents - full technical, clinical, manufacturing data
- **§814.82**: Postapproval requirements - annual reports, periodic safety updates
- **§814.124**: Periodic reports - annual post-approval studies, safety updates

**PMA Modules:**
1. Administrative (cover letters, fees, certifications)
2. Device description (specifications, materials, performance)
3. Nonclinical studies (bench, animal, biocompatibility)
4. Clinical studies (protocols, data, statistical analysis)
5. Labeling (all proposed labeling materials)

#### Part 820 - Quality System Regulation (QSR)
**Key Sections:**
- **§820.20**: Management responsibility - quality policy, resources, management review
- **§820.30**: Design controls - DHF, design planning, input, output, review, verification, validation, changes, history file
- **§820.50**: Purchasing controls - supplier evaluation, purchasing data
- **§820.70**: Production and process controls - manufacturing procedures, environmental controls
- **§820.80**: Receiving, in-process, and final acceptance activities
- **§820.90**: Nonconforming product - identification, segregation, disposition
- **§820.100**: Corrective and preventive action (CAPA) - investigation, verification, validation
- **§820.181**: Device master record (DMR) - specifications, procedures, manufacturing instructions
- **§820.184**: Device history record (DHR) - traceability, lot/serial records
- **§820.198**: Complaint files - review, evaluation, investigation

**QSR Application:**
- Applies to all finished device manufacturers
- Contract manufacturers also subject to QSR
- Exemptions exist for certain Class I devices
- International equivalent: ISO 13485:2016

#### Part 860 - Medical Device Classification
**Key Sections:**
- **§860.7**: Classification criteria - intended use, level of risk
- **§860.120**: De Novo classification process for novel devices
- **§860.130**: General procedures for classification changes

**Classification Factors:**
- Intended use and indications
- Level of patient contact (non-contact, external, invasive, implant)
- Duration of use (temporary <60 min, short-term <30 days, long-term >30 days)
- Life-sustaining or life-supporting
- Likelihood of serious adverse events

### Drug Regulations

#### Part 312 - Investigational New Drug Application (IND)
**Key Sections:**
- **§312.20**: General requirements - sponsor responsibilities
- **§312.23**: IND content and format
  - Introductory statement and general investigational plan
  - Investigator's brochure
  - Protocols (objectives, design, monitoring)
  - Chemistry, manufacturing, and controls (CMC)
  - Pharmacology and toxicology
  - Previous human experience
- **§312.32**: IND safety reporting - serious and unexpected adverse events within 15 calendar days

**IND Types:**
- **Investigator IND**: Physician initiates and conducts study
- **Emergency IND**: Single patient emergency use
- **Treatment IND**: Expanded access for seriously ill patients

#### Part 314 - New Drug Applications (NDA)
**Key Sections:**
- **§314.50**: NDA content requirements
  - Module 1: Administrative
  - Module 2: Summaries (overall summary, clinical summary, nonclinical summary)
  - Module 3: Quality (CMC, drug substance, drug product)
  - Module 4: Nonclinical study reports
  - Module 5: Clinical study reports
- **§314.80**: Postmarketing reporting - adverse events, annual reports
- **§314.94**: ANDA content - bioequivalence demonstration

**NDA Review Process:**
- Day 0: Submission
- Day 60: Filing decision (refuse to file if inadequate)
- Day 74: Filing communication to sponsor
- Month 6 (Priority) or Month 10 (Standard): PDUFA action date
- Advisory Committee meeting (if needed): typically months 6-8

#### Part 600-680 - Biologics
**Key Sections:**
- **Part 600**: General biologics standards
- **Part 601**: BLA requirements
  - §601.2: Applications for biologics licenses
  - §601.12: Changes to approved application
- **Part 606**: Blood product regulations
- **Part 610**: General biological product standards
- **Part 660**: Additional standards for specific biologics

**BLA Specifics:**
- Manufacturing site approval required
- Lot release for certain products
- Facility inspection often before approval
- Similar review timeline to NDA

---

## FDA Review Timelines

### MDUFA V Performance Goals (Medical Devices, 2023-2027)

| Submission Type | FDA Goal (Days) | Target Achievement Rate |
|----------------|----------------|------------------------|
| 510(k) - Standard | 90 | 95% |
| 510(k) - Special/Abbreviated | 90 | 95% |
| De Novo | 150 | 70% |
| PMA - Original | 180 | 90% |
| PMA - Panel Track | 285 (includes panel) | 70% |
| PMA Supplements (180-day) | 180 | 90% |
| PMA Supplements (Real-time) | 30 | 90% |
| 510(k) Refuse to Accept (RTA) Decision | 15 | 95% |

**Reality Check:**
- Many 510(k)s receive additional information requests, extending timeline
- Average 510(k) end-to-end: 3-6 months
- PMA reviews often take longer than goal due to data questions
- Panel reviews add 3-6 months to PMA timeline

### PDUFA VII Performance Goals (Drugs/Biologics, 2023-2027)

| Application Type | Priority Review | Standard Review |
|-----------------|-----------------|-----------------|
| NDA/BLA - Original | 6 months | 10 months |
| NDA/BLA - Resubmission (Class 1) | 2 months | 6 months |
| NDA/BLA - Resubmission (Class 2) | 2 months | 6 months |
| Efficacy Supplements | 4 months | 10 months |
| Manufacturing Supplements | Variable | Variable |

**Priority Review Criteria:**
- Significant improvement in safety or effectiveness
- Serious condition with unmet medical need
- Designated as Fast Track, Breakthrough Therapy, or Regenerative Medicine Advanced Therapy

**Reality Check:**
- Refuse to File (RTF) decision at day 60 if application inadequate
- Complete Response Letter (CRL) if approval cannot be granted
- Resubmission clocks vary based on whether new clinical data needed

---

## Device Risk Classification

### FDA Device Classes

#### Class I - Low Risk (General Controls)

**Characteristics:**
- Minimal potential for harm
- Simple design and use
- General controls sufficient for safety and effectiveness

**Regulatory Requirements:**
- Establishment registration and device listing
- Good manufacturing practices (limited to certain devices)
- Labeling requirements
- Premarket notification (510(k)) for most devices is **exempt**

**Examples:**
- Elastic bandages
- Examination gloves
- Manual surgical instruments (scissors, forceps)
- Stethoscopes
- Mercury thermometers

**Percentage:** ~47% of all medical devices

#### Class II - Moderate Risk (Special Controls)

**Characteristics:**
- Moderate potential for harm if misused
- General controls insufficient alone
- Special controls can mitigate risk

**Regulatory Requirements:**
- All Class I requirements
- Premarket notification (510(k)) required (unless exempt)
- Special controls:
  - Performance standards
  - Postmarket surveillance
  - Patient registries
  - Guidance documents
  - Special labeling requirements

**Examples:**
- Powered wheelchairs
- Infusion pumps
- Pregnancy test kits
- Blood pressure cuffs
- Surgical drapes
- X-ray machines

**Percentage:** ~43% of all medical devices

**510(k) Exemptions:**
Some low-risk Class II devices are exempt from 510(k) but still require compliance with special controls.

#### Class III - High Risk (Premarket Approval)

**Characteristics:**
- Highest risk to patient safety
- Support or sustain life
- Prevent impairment of health
- Present unreasonable risk of illness/injury
- General and special controls insufficient

**Regulatory Requirements:**
- All Class I and II requirements
- Premarket Approval (PMA) required
- Clinical data demonstrating safety and effectiveness
- Manufacturing facility inspection
- Postmarket surveillance often required

**Examples:**
- Implantable pacemakers
- Heart valves
- HIV diagnostic tests
- Silicone breast implants
- Left ventricular assist devices (LVADs)
- Deep brain stimulators

**Percentage:** ~10% of all medical devices

**Pathways to Class III:**
- Automatic Class III designation for novel devices (can request De Novo to reclassify to I or II)
- Life-sustaining or life-supporting devices
- Implanted devices with significant risk

### Risk Assessment Factors

**Patient Contact:**
- **Non-contact**: Lowest risk (e.g., in vitro diagnostic equipment)
- **External contact**: Low risk (e.g., electrodes, external prosthetics)
- **Invasive**: Moderate risk (e.g., catheters, surgical instruments)
- **Implant**: Higher risk (e.g., orthopedic implants, pacemakers)

**Duration of Use:**
- **Temporary**: <60 minutes (e.g., surgical instruments)
- **Short-term**: <30 days (e.g., temporary catheters)
- **Long-term**: >30 days (e.g., implants)

**Critical to Life:**
- **Life-sustaining**: Failure results in death (e.g., ventilators for dependent patients)
- **Life-supporting**: Prevents health impairment (e.g., dialysis machines)

**Technology Risk:**
- Novel technology without precedent
- Complex software/AI components
- Nanotechnology or novel materials
- Energy-emitting (radiation, ultrasound, etc.)

---

## Common FDA Guidance Documents

### Medical Device Guidance

#### General Device Guidance

**510(k) Program:**
- **"The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications"** (July 2014)
  - How to demonstrate substantial equivalence
  - Comparison methodology
  - When clinical data needed

**De Novo:**
- **"De Novo Classification Process (Evaluation of Automatic Class III Designation)"** (October 2021)
  - When to use De Novo
  - Acceptance criteria
  - Special controls development

**Design Controls:**
- **"Design Control Guidance for Medical Device Manufacturers"** (March 1997)
  - Design and development planning
  - Design input requirements
  - Design output specifications
  - Design review, verification, validation
  - Design transfer and changes
  - Design history file maintenance

**Quality System:**
- **"Medical Device Quality Systems Manual: A Small Entity Compliance Guide"** (1997)
  - QSR implementation for small manufacturers
  - Examples and case studies

#### Software and Digital Health

**Software as Medical Device:**
- **"Policy for Device Software Functions and Mobile Medical Applications"** (September 2022)
  - What constitutes a medical device
  - Enforcement discretion categories
  - Clinical decision support software

**Clinical Decision Support:**
- **"Clinical Decision Support Software"** (September 2022)
  - CDS software that is NOT a device
  - Four criteria for non-device CDS
  - Examples and case studies

**AI/ML:**
- **"Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan"** (January 2021)
  - Predetermined change control plans
  - Good Machine Learning Practice (GMLP)
  - Patient-centered approach to transparency

**Content of Submissions:**
- **"Content of Premarket Submissions for Device Software Functions"** (November 2023)
  - Level of concern determination
  - Software documentation requirements
  - Validation and verification

**Cybersecurity:**
- **"Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions"** (September 2023)
  - Threat modeling
  - Security risk management
  - Software bill of materials (SBOM)

#### Clinical and Preclinical

**IDE:**
- **"Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies"** (October 2013)
  - Early feasibility studies
  - Significant risk determination
  - Informed consent

**Biocompatibility:**
- **"Use of International Standard ISO 10993-1, 'Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process'"** (June 2020, updated September 2020)
  - Biological risk assessment
  - Endpoints to evaluate
  - Testing strategies

### Drug/Biologic Guidance

#### IND/NDA Process

**IND Applications:**
- **"IND Applications Prepared and Submitted by Sponsor-Investigators"** (October 2022)
  - Content and format
  - Regulatory requirements
  - Common deficiencies

**Common Technical Document (CTD):**
- **"M4E(R2): The CTD – Efficacy"** (November 2016, ICH)
  - Clinical study reports format
  - Efficacy summary structure

**Expedited Programs:**
- **"Expedited Programs for Serious Conditions – Drugs and Biologics"** (May 2022)
  - Fast Track designation
  - Breakthrough Therapy designation
  - Accelerated Approval
  - Priority Review

#### Clinical Trials

**Adaptive Designs:**
- **"Adaptive Designs for Clinical Trials of Drugs and Biologics"** (November 2019)
  - Types of adaptations
  - Statistical considerations
  - Regulatory interactions

**Biostatistics:**
- **"E9 Statistical Principles for Clinical Trials"** (September 1998, ICH)
  - Study design
  - Statistical analysis
  - Multiple comparisons

#### Manufacturing

**Process Validation:**
- **"Process Validation: General Principles and Practices"** (January 2011)
  - Stage 1: Process Design
  - Stage 2: Process Qualification
  - Stage 3: Continued Process Verification

**Quality by Design:**
- **"Q8(R2) Pharmaceutical Development"** (November 2009, ICH)
  - Design space concept
  - Quality risk management
  - Control strategy

---

## FDA Contact Information

### Center for Devices and Radiological Health (CDRH)

**General Inquiries:**
- Phone: 1-800-638-2041
- Email: DICE@fda.hhs.gov (Division of Industry and Consumer Education)

**Premarket Submissions:**
- 510(k): OPEQ510K@fda.hhs.gov
- De Novo: denovo@fda.hhs.gov
- PMA: OMB.ODE@fda.hhs.gov
- IDE: IDE@fda.hhs.gov

**Postmarket:**
- Medical Device Reporting: devicereports@fda.hhs.gov
- Recalls: recalls@fda.hhs.gov

### Center for Drug Evaluation and Research (CDER)

**General Inquiries:**
- Phone: 1-855-543-3784 (1-855-5-INFO-FDA)
- Email: druginfo@fda.hhs.gov

**Division-Specific:** Contact appropriate review division based on therapeutic area

### Center for Biologics Evaluation and Research (CBER)

**General Inquiries:**
- Phone: 1-800-835-4709
- Email: ocod@fda.hhs.gov (Office of Communication, Outreach and Development)

### FDA Regional Offices (for Inspections)

**Northeast Region:**
- Location: Jamaica, NY
- Coverage: CT, MA, ME, NH, NJ, NY, PR, RI, VT, VI

**Central Region:**
- Location: Chicago, IL
- Coverage: IA, IL, IN, MI, MN, ND, OH, SD, WI

**Southeast Region:**
- Location: Atlanta, GA
- Coverage: AL, FL, GA, KY, LA, MS, NC, SC, TN, VA

**Southwest Region:**
- Location: Dallas, TX
- Coverage: AR, CO, KS, MO, NM, OK, TX, UT, WY

**Pacific Region:**
- Location: Irvine, CA
- Coverage: AK, AZ, CA, GU, HI, ID, MT, NV, OR, WA

---

## FDA Acronyms & Definitions

### Common Acronyms

**A-B**
- **ANDA**: Abbreviated New Drug Application (generic drugs)
- **BAA**: Business Associate Agreement (HIPAA)
- **BIMO**: Bioresearch Monitoring Program
- **BLA**: Biologics License Application

**C**
- **CAPA**: Corrective and Preventive Action
- **CBER**: Center for Biologics Evaluation and Research
- **CDER**: Center for Drug Evaluation and Research
- **CDRH**: Center for Devices and Radiological Health
- **CFR**: Code of Federal Regulations
- **cGMP**: Current Good Manufacturing Practices
- **CRO**: Contract Research Organization
- **CTD**: Common Technical Document

**D-E**
- **DHF**: Design History File
- **DMR**: Device Master Record
- **DHR**: Device History Record
- **EUA**: Emergency Use Authorization

**F-H**
- **FDA**: Food and Drug Administration
- **GCP**: Good Clinical Practice
- **GLP**: Good Laboratory Practice
- **GMLP**: Good Machine Learning Practice
- **GUDID**: Global Unique Device Identification Database
- **HDE**: Humanitarian Device Exemption

**I-L**
- **ICH**: International Council for Harmonisation
- **IDE**: Investigational Device Exemption
- **IND**: Investigational New Drug Application
- **IRB**: Institutional Review Board
- **ISO**: International Organization for Standardization
- **IVD**: In Vitro Diagnostic

**M-P**
- **MAUDE**: Manufacturer and User Facility Device Experience (adverse events database)
- **MDR**: Medical Device Reporting
- **MDSAP**: Medical Device Single Audit Program
- **MDUFA**: Medical Device User Fee Amendments
- **NDA**: New Drug Application
- **PAS**: Post-Approval Study
- **PDUFA**: Prescription Drug User Fee Act
- **PMA**: Premarket Approval

**Q-S**
- **Q-Sub**: Q-Submission (request for feedback)
- **QSR**: Quality System Regulation (21 CFR Part 820)
- **RTA**: Refuse to Accept
- **SaMD**: Software as a Medical Device
- **SE**: Substantially Equivalent

**T-U**
- **TRL**: Technology Readiness Level
- **UDI**: Unique Device Identification

### Key Definitions

**Substantial Equivalence (SE):**
A device is substantially equivalent to a predicate device if it:
- Has the same intended use, AND
- Has the same technological characteristics, OR
- Has different technological characteristics but does not raise new questions of safety/effectiveness and demonstrates equivalence through performance data

**Predicate Device:**
A legally marketed device to which a new device is compared in a 510(k) submission to demonstrate substantial equivalence. Must be:
- Legally marketed in the US
- Not subject to PMA or De Novo that was granted under unique or special controls
- Not one that FDA has determined should be subject to PMA

**Intended Use:**
The general purpose of the device or its function. Example: "To measure blood glucose levels for diabetes management."

**Indications for Use:**
The disease or condition the device will diagnose, treat, prevent, cure, or mitigate. More specific than intended use. Example: "For prescription use only for self-testing by people with diabetes mellitus as an aid in monitoring blood glucose control."

**Level of Concern (Software):**
- **Minor**: Failure or latent design flaw unlikely to result in injury
- **Moderate**: Failure or latent flaw could result in minor injury
- **Major**: Failure or latent flaw could result in serious injury or death

**Significant Risk Device (for IDE):**
A device that:
- Is intended as an implant and presents a potential for serious risk to health, safety, or welfare
- Is purported or represented to be for use supporting or sustaining human life and presents potential for serious risk
- Is for use of substantial importance in diagnosing, curing, mitigating, or treating disease or preventing impairment and presents potential for serious risk
- Otherwise presents potential for serious risk to health, safety, or welfare

**Combination Product:**
A product composed of any combination of drug, device, or biologic. Examples:
- Drug-eluting stent (device + drug)
- Prefilled syringe (drug + device)
- Gene therapy (biologic + device for delivery)

---

## Notes on Using This Reference

**Currency:**
- FDA regulations and guidance are updated periodically
- Always verify current versions on FDA.gov
- Subscribe to FDA email updates for your product category

**Interpretation:**
- This guide provides general information
- Specific situations may require detailed regulatory analysis
- Consider consulting FDA through Q-Submission or Pre-Submission for novel products

**International:**
- This guide focuses on US FDA requirements
- International markets (EU, Canada, Japan, etc.) have different requirements
- Consider MDSAP for multi-country quality system compliance

---

**Last Updated:** 2024-11-16
**Version:** 1.0.0
**Next Review:** 2025-02-16 (quarterly updates)

For the most current information, always consult:
- FDA.gov official website
- 21 CFR (via ecfr.gov)
- FDA Guidance Document database
- FDA databases (510(k), PMA, De Novo, Drugs@FDA)
